Loading stock data…
$0.23-0.02 (-6.47%)
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
AEON Biopharma, Inc. in the Healthcare sector is trading at $0.23 with a market capitalization of $13M. Wall Street consensus targets $1.82 (5 analysts), implying a +692.3% move over the next 12 months. The stock is currently near its 52-week low of $0.18, remaining 68.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.93M↑ | -$5.94M↓ | -$5.50M↓ | -$2.53M↑ | -$4.32M |
| Net Income | -$1.16M↑ | -$11.79M↑ | -$37.14M↓ | -$4.54M↑ | -$6.64M |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervi...